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Background: The aim of this study was to compare the efficacy of antagonist rescue protocol (replacing GnRH agonist
with GnRH antagonist and reducing the dose of gonadotropins) combined with cabergoline versus cabergoline alone
in the prevention of ovarian hyperstimulation syndrome (OHSS) in patients pretreated with GnRH agonist long protocol
who were at high risk for OHSS.
Methods: Two hundred and thirty six patients were randomized in a 1:1 ratio to the cabergoline group or the
antagonist rescue combined with cabergoline group. Both groups received oral cabergoline (0.5 mg/day) for eight days
beginning on the day of HCG administration. In the antagonist rescue combined with cabergoline group, when the
leading follicle reached 16 mm, GnRH agonist (triptorelin) was replaced with GnRH antagonist (cetrorelix acetate) and
the dose of HP-uFSH was reduced to 75 IU/day. HCG (5,000 IU/I.M) was administered when the serum estradiol level
dropped below 3500 pg/ml. The study was open label and the outcome assessors (laboratory staff and the doctor who
performed oocyte retrieval) were blind to treatment allocation.
Results: The incidence of moderate/severe OHSS was significantly lower in the antagonist rescue combined with
cabergoline group [5.08 % Vs 13.56 %, P value =0.025, OR = 0.342, 95 % CI, 0.129–0.906]. Four cycles were cancelled in
the cabergoline group. There were no significant differences between the groups with respect to the number of
retrieved oocytes, metaphase II oocytes, high quality embryos and fertilization rate. Moreover, the implantation and
pregnancy rates were comparable between both groups.
Conclusion: GnRH antagonist rescue protocol combined with cabergoline is more effective than cabergoline alone in
the prevention of OHSS.
Trial registration: Clinical trial.gov (NCT02461875).
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Ovarian hyperstimulation syndrome (OHSS) is the most
dangerous iatrogenic complication associated with
ovarian stimulation. Cystic enlargement of the ovaries,
increased capillary permeability and fluid shift from the
intravascular space into the third space are the main
characteristics of OHSS [1].
Several strategies have been proposed to prevent or
minimize the intensity of OHSS. Cycle cancellation,
withholding gonadotropins administration and postpon-
ing human chorionic gonadotropin (HCG) injection till
HCG drops to a safe level (coasting),antagonist rescue
protocol, embryos freezing, minimal stimulation IVF,
in vitro maturation of oocytes, metformin administration
in patients with polycystic ovary syndrome, natural cycle
IVF, triggering ovulation with a reduced dose of HCG or
with GnRH agonist in GnRH antagonists stimulation
cycle and administration of GnRH antagonist after
oocyte retrieval have all been used. Apart from cycle
cancelation, none of these strategies have been effective
in the complete prevention of OHSS [1, 2].
The primary pathophysiological feature of OHSS is
increased capillary permeability, which results in fluid shift
to the third space. It appears that the main cause of in-
creased capillary permeability is the release of vasoactive-
angiogenic substances (interleukins, tumor necrosis factor
(TNF) α, endothelin and vascular endothelial growth fac-
tor (VEGF)) from the ovaries in response to exogenous or
endogenous HCG [1, 2]. Moreover, several authors sug-
gested that the circulating peripheral blood mononuclear
cells may be involved in the pathophysiology of OHSS. In
vitro studies, revealed that HCG stimulates the produc-
tion of IL8 and VEGF by monocytes [3]. Kosaka et al.
[4] observed that peripheral blood mononuclear cells of
patients with OHSS produce excessive amounts of
VEGF. Several studies have revealed that VEGF is the
primary vasoactive-angiogenic substance responsible
for the development of OHSS. VEGF stimulates neovascu-
larization and increased capillary permeability by interact-
ing with VEGF receptor 2 (VEGFR-2). Gonadotropins
stimulate the expression of VEGF and VEGFR-2 mRNA
in granulosa cells and HCG (exogenous or endogenous)
accentuates this expression [5, 6].
Recent animal and human studies have revealed that
dopamine agonists antagonize VEGF dependent vascular
permeability by inhibiting VEGFR-2 phosphorylation and
signaling. The use of cabergoline (a dopamine receptor-2
agonist) in the prevention of OHSS has been investigated
in several studies. Three meta-analyses have revealed that
cabergoline reduces the incidence of moderate/severe
OHSS without affecting implantation, pregnancy and
miscarriage rates [2, 6, 7].
Antagonist rescue protocol (replacing GnRH agonist
with GnRH antagonist and reducing the dose ofgonadotropins) is another effective strategy for pre-
venting OHSS. Several studies have shown that the
antagonist rescue protocol causes a rapid reduction in
the estradiol level, prevents cycle cancelation, and re-
duces the risk of moderate/severe OHSS [8, 9].
Recently, Rollene et al. [10] reported the use of caber-
goline and GnRH antagonist (ganirelix) in the outpatient
treatment of four patients with OHSS. Cabergoline
combined with ganirelix resulted in rapid resolution of
the clinical symptoms of OHSS. None of the patients re-
quired hospitalization.
The aim of this study was to compare the efficacy
of antagonist rescue protocol combined with cabergo-
line versus cabergoline alone in the prevention of ovarian
hyperstimulation syndrome (OHSS) in patients pretreated
with GnRH agonist long protocol who were at high risk
for OHSS.
Methods
During the period between March 2013 and December
2015, this prospective, two arm, assessor blinded, ran-
domized controlled trial was conducted at the assisted
conception unit of Aljazeera (Al Gazeera) hospital, Giza,
Egypt. The study protocol followed the CONSORT
guidelines for reporting parallel group randomised trials
[11]. This study included 236 patients who were stimu-
lated using the long luteal GnRH agonist protocol and at
high risk for developing OHSS [have more than 20 folli-
cles (90 % of them less than 14 mm in mean diameter)
and serum estradiol ≥ 3000 pg/ml] [9]. The exclusion
criteria were an age less than 18 years or more than
37 years, endometriosis, presence of submucous or
intramural myoma of more than 5 cm, recurrent abor-
tion and a previous IVF-ET cycle. Patients with lung
fibrosis, swelling or inflammation around the heart or
lung, hypertension, liver disease, heart valve disease, or an
allergy to cabergoline or ergot derivatives were also ex-
cluded from the study. The ethics committee of the hospital
approved the study protocol [N-2-2013] and the patients
provided informed consent before randomization. The
study was registered at clinical trials.gov [NCT02461875].
Patients were randomized to the cabergoline group and
the antagonist rescue combined with cabergoline group
using a computer generated randomization list (obtained
from http://graphpad.com/quickcalcs/randomN1.cfm) and
sequentially numbered sealed envelopes containing alloca-
tion information written on a card. The randomization list
and sealed envelopes were prepared by a statistician
who was not involved in the allocation process. The
sequentially numbered envelopes were opened by the
study nurse and the patients were informed of their
assigned group. The laboratory staff and the doctor
who performed oocyte retrieval (Fouda U.M) were
blinded to the treatment received.
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using the long luteal GnRH agonist protocol [12]. Trip-
torelin (Decapeptyl, Ipsen, Slough, United Kingdom) at a
daily dose of 0.1 mg/S.C was started one week before an-
ticipated menstruation. In PCOS patients with oligo-
menorrhea or amenorrhea, medroxyprogesterone acetate
tablets (Provera Pfizer, Inc., New York, NY) (5 mg twice
daily) were administered orally for 5 days to induce
withdrawal bleeding. Following withdrawal bleeding, the
patients received a 3-week course of combined oral
contraception pills (Gynera, Bayer-Shering, Pharma-AG,
Germany) from day 2 of menstruation. Triptorelin
(0.1 mg/day) was started from day 20 of the cycle. After
confirmation of pituitary down regulation (serum E2
levels less than 50 pg/ml and endometrial thickness less
than 5 mm) highly purified urinary FSH(HP-uFSH)
(Fostimon, IBSA, Switzerland) was administered. The
starting gonadotropins dose was determined according
to the age, antral follicle count, basal FSH and E2 levels
and body mass index. Follicular development was moni-
tored by transvaginal ultrasonography and serum
estradiol. The starting dose of gonadotropins was not
adjusted during stimulation.
In cabergoline group, cabergoline (Dostinex; Pfizer, Italy)
at a daily dose of 0.5 mg was administered orally at bed
time for 8 days starting on the day of HCG administration.
HCG (Pregnyl; N.V. Organon, Oss, Holland) at a dose
of 5,000 IU/I.M was administered when three or
more follicles ≥ 18 mm in diameter were detected by
ultrasound examination.
In antagonist rescue combined with cabergoline group,
when the leading follicle reached 16 mm, HP-uFSH was
continued at a daily dose of 75 IU until and including
the day of HCG administration. Triptorelin was discon-
tinued and GnRH antagonist (Cetrorelix acetate)(Cetro-
tide; Serono International S.A., Geneva, Switzerland)
0.25 mg/S.C was administered daily until and including
the day of HCG administration. Serum estradiol was
measured daily and HCG (5,000 IU/I.M) was adminis-
tered when the serum estradiol level dropped below
3500 pg/ml. Moreover, cabergoline (0.5 mg/day) was
administered orally at bed time for 8 days starting on
the day of HCG administration.
Oocyte retrieval was performed under deep sedation
36 ± 2 h after HCG administration. Two or three em-
bryos were transferred 3 days after oocyte retrieval.
Pregnancy test was performed two weeks after embryo
transfer. Transvaginal ultrasound was performed five
weeks after embryo transfer to detect the presence of
intrauterine gestational sac.
The luteal phase was supported with progesterone
vaginal pessaries (Prontogest, Marcyrl, Egypt) 400 mg
twice daily, starting on the day of oocyte retrieval until
12 weeks gestation or negative B-subunit HCG. Theoccurrence and severity of OHSS was defined according
to the classification described by Golan et al. [13]. The
detection of ascites by ultrasound examination in
patients with features with mild OHSS (enlarged ovaries
(5–12 cm), abdominal discomfort, nausea, vomiting and
diarrhea) indicated the occurrence of moderate OHSS.
The presence of clinically evident ascites and/or hydro-
thorax, increased blood viscosity and coagulation abnor-
mality indicated the occurrence of severe OHSS.
Patients with severe OHSS were hospitalized. OHSS
with an onset ≤ 10 days from oocyte retrieval was de-
fined as early onset OHSS and OHSS with later onset
was defined as late onset OHSS.
Clinical and ultrasound examinations were performed
on the day of embryo transfer and after 4, 8 and 14 days
to detect the occurrence of OHSS. All patients were
instructed to contact us if they experienced difficulty in
breathing, decreased urine volume, dizziness on stand-
ing, abdominal pain, enlargement of the abdomen and
rapid weight gain.
The primary outcome measure was the incidence of
moderate/severe OHSS and the secondary outcome
measures were the number of retrieved oocytes, meta-
phase II oocytes, fertilization rate, implantation rate,
miscarriage rate, clinical pregnancy rate (presence of
intrauterine gestational sac detected by transvaginal
ultrasound), and ongoing pregnancy rate (pregnancies
continued beyond 20 weeks).
Sample size calculation
At the time of study design, a Cochrane review revealed
that the incidence of moderate or severe OHSS in pa-
tients at high risk of developing OHSS treated with
cabergoline was 16.95 % [2]. We considered that 11.95 %
difference in the incidence of moderate/severe OHSS be-
tween the group of patients treated with cabergoline
alone and the group of patients treated with the antag-
onist rescue protocol combined with cabergoline would
be of clinical significance. To detect an 11.95 % differ-
ence in the incidence of moderate/severe OHSS between
both groups, 107 patients would have to be recruited to
each group of the study to achieve a study power of
80 % at a significance level of 0.05 (calculated on https//
www.sealedenvelope.com/power/continuous-superiority).
We expected that the dropout incidence would be 10 %;
therefore, 118 patients were recruited to each arm of
the study.
Statistical analysis
Statistical analysis was performed using student’s t test
and χ2 test, as appropriate. Fisher’s exact test was used
when the expected frequency was less than 5. A prob-
ability value (P value) less than 0.05 was considered
statistically significant. All statistical calculations were
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NY, USA) and SPSS (SPSS, Chicago, IL, USA). Absolute
risk reduction (95 % CI) and number needed to treat
(95 % CI) were calculated on http://graphpad.com/
quickcalcs/NNT1/. An intention to treat analysis and
per protocol analysis were performed.
Results
Between March 2013 and December 2015, 2458 IVF-ET
cycles were performed in our institution. Among the 334
patients who were at high risk for OHSS, 88 patients did
not meet the inclusion criteria and 10 patients declined to
participate in the study. We enrolled 236 patients with
118 patients randomized to each arm of the study. The
flow of the patients in the study is shown in Fig. 1.
There were no significant differences between both
groups with respect to age, body mass index (BMI),
duration of infertility, cause of infertility, antral follicle
count and baseline hormonal profile (Table 1).
The serum estradiol level on the day of HCG adminis-
tration was significantly higher in the cabergoline group
than in the antagonist rescue combined with cabergoline
group (5501 ± 1122 Vs. 2811 ± 399 pg/ml, P value < 0.001)
(Table 2).
In the antagonist rescue combined with cabergoline
group, the mean (SD) number of antagonist injections
needed to reduce the estradiol level below 3500 pg/ml
was 1.52(0.69). Seventy patients (59.32 %) required one
GnRH antagonist dose, 35 patients (29.66 %) required
two GnRH antagonist doses and 13 patients (11.02 %)
required three GnRH antagonist doses to reduce the es-
tradiol levels below 3500 pg/ml. The mean serumFig. 1 The flow of the patients in the studyestradiol dropped by 34.56 % after the first 24 h of
GnRH antagonist administration (5101 Vs. 3338 pg/ml).
The drop in the serum estradiol level continued after the
second and the third GnRH antagonist injections.
The incidence of moderate/severe OHSS was signifi-
cantly lower in the antagonist rescue combined with
cabergoline group [5.08 % Vs 13.56 %, P value =0.025,
OR = 0.342, 95 % CI,0.129–0.906]. Absolute risk reduc-
tion was 8.48 % (95 % CI, 1.14 %–15.81 %) and number
needed to treat was 12 (95 % CI, 6.3–88.1). Four patients
in the cabergoline group had severe OHSS and none of
the patients in the antagonist group had severe OHSS.
Four cycles were cancelled in the cabergoline group and
no cycles were cancelled in the antagonist rescue com-
bined with cabergoline group (Table 2).
All patients in the antagonist rescue combined with
cabergoline group received 75 IU/day of HP-uFSH when
the leading follicle reached 16 mm and all patients in
the cabergoline group received at least 150 IU/day of
HP-uFSH during the stimulation period. The total go-
nadotropins dose administered till the leading follicle
reached 16 mm was comparable between both groups
[25.39 ± 5.64 Vs. 24.32 ± 6.62 ampules, P value = 0.184].
Conversely, the total gonadotropins dose administered
after the leading follicle reached 16 mm was signifi-
cantly lower in the antagonist rescue combined with
cabergoline group (2.48 ± 0.64 Vs. 5.56 ± 1.92 ampules,
P value < 0.001).
There were no significant differences in the number of
retrieved oocytes, metaphase II oocytes, fertilized oocytes,
high quality embryos (grade 1 or 2) and fertilization rate be-
tween the two groups (Table 2). Moreover, the implantation








Age (years) 27.35 ± 5.98 26.69 ± 5.58 0.387
Body mass index (Kg/m2) 25.85 ± 4.54 26.47 ± 4.23 0.28
Duration of infertility
(years)
5.76 ± 2.65 6.14 ± 2.58 0.275
Type of infertility
• Primary 102/118(86.44 %) 97/118(82.2 %) 0.371
• Secondary 16/118(13.56 %) 21/118(17.8 %) 0.371
Basal FSH (IU/L) 6.29 ± 1.53 6.31 ± 1.48 0.897
Antral follicle count 21.46 ± 4.17 22.05 ± 3.75 0.252
Patients with amenorrhea
or oligomenorrhea
12/118(10.17 %) 14/118(11.86 %) 0.678
Cause of infertility
• Tubal Factor 31/118(26.27 %) 40/118(33.9 %) 0.202
• PCOS 32/118(27.12 %) 29/118(24.58 %) 0.656
• Unexplained 17/118(14.41 %) 12/118(10.17 %) 0.322
• Male Factor 20/118(16.95 %) 22/118(18.64 %) 0.734
• Two or more factors 18/118(15.25 %) 15/118(12.71 %) 0.573
PCOS polycystic ovary syndrome
Values are expressed as mean ± SD or n/n(%)
Table 2 Outcome of ovarian stimulation
Cabergoline








9.92 ± 0.85 10.08 ± 0.68 0.129
Total HP-uFSH
ampoules (75U)
29.88 ± 6.8 27.87 ± 5.58 0.014
Estradiol level on the
HCG day (pg/ml)
5501 ± 1122 2811 ± 399 <0.001
No. of retrieved
oocytes
19.09 ± 4.01 18.85 ± 4.37 0.651
No. of metaphase II
oocytes
17.02 ± 3.8 16.97 ± 3.94 0.933
No. of fertilized
oocytes
13.69 ± 3.32 13.42 ± 3.08 0.523
Fertilization rate 1584/2003(79.08 %) 1561/1940(80.46 %) 0.28
No. of high quality
embryos
4.02 ± 1.28 3.84 ± 1.31 0.295
No. of embryos
transferred
2.32 ± 0.47 2.26 ± 0.44 0.303
Cycles cancelled 4/118(3.39 %) 0/118(0 %) 0.122
Moderate or severe
OHSS
16/118(13.56 %) 6/118(5.08 %) 0.025
Moderate OHSS 12/118(10.17 %) 6/118(5.08 %) 0.141
Severe OHSS 4/118(3.39 %) 0/118(0 %) 0.122
Early onset OHSS 12/118(10.17 %) 5/118(4.24 %) 0.078
Late onset OHSS 4/118(3.39 %) 1/118(0.85 %) 0.37
OHSS ovarian hyperstimulation syndrome
Values are expressed as mean ± SD or n/n(%)
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able between the two groups (Table 3). A case of ectopic
pregnancy was reported in the antagonist rescue combined
with cabergoline group.
Discussion
The data presented in this study revealed that GnRH
antagonist rescue protocol combined with cabergoline
minimized the risk of moderate/severe OHSS and pre-
vented cycle cancelation without affecting the number of
oocytes retrieved, quality of embryos and implantation
and pregnancy rates in patients at high risk for OHSS who
were pretreated with GnRH agonist long protocol. To our
knowledge, this is the first randomized controlled study
that evaluated the role of antagonist rescue protocol com-
bined with cabergoline in minimizing the risk of OHSS.
The presence of a large number of growing follicles
and rapidly rising estradiol level are associated with an
increased likelihood of developing OHSS. The causative
role of estradiol in inducing OHSS has not been proved.
It seems that patients with a large number of growing
follicle have a large mass of granulosa cells that produce
excessive amounts of estradiol and chemical mediators
that are responsible for OHSS [14]. Several authors have
proposed several strategies, such as coasting and antag-
onist rescue protocol, to reduce estradiol levels in an
effort to minimize the risk of OHSS [8, 9, 15, 16].Coasting is one of the most commonly used preventive
measures for OHSS. With this management strategy, go-
nadotropins administration is stopped, GnRH agonist
administration is continued and HCG administration is
delayed until estradiol drops to a safe level (≤3000 pg/
ml). Withholding gonadotropins administration induces
apoptosis of granulosa cells and therefore minimizes the
production of estradiol and chemical mediators respon-
sible for the development of OHSS [15, 16]. Previous
studies revealed that the duration of coasting is an
important predictor of IVF outcomes. It seems that pro-
longed complete deprivation of gonadotropins (>3 days)
is associated with a decrease in the number of oocytes
retrieved, implantation rate and clinical pregnancy rate
[17, 18]. Antagonist rescue of agonist IVF cycles at risk
of OHSS was first described by Gustafson et al. [8]. In a
retrospective study including 87 patients down-regulated
with GnRH agonist who were at risk of OHSS, GnRH
agonist was switched to GnRH antagonist in patients
who failed to response to reducing the dose of gonado-
tropins. HCG was administered when the serum estra-
diol level fell to a safe level (<3000 pg/ml). Antagonist
Table 3 Reproductive outcomes
Cabergoline group (n = 118) Antagonist rescue combined
with cabergoline group (n = 118)
Odd ratio (95 % CI) P value
Clinical pregnancy/started cycle 42/118(35.59 %) 46/118(38.98 %) 0.87[0.51–1.47] 0.59
Clinical pregnancy/transfer cycle 42/114(36.84 %) 46/118(38.98 %) 0.91[0.54–1.55] 0.74
Ongoing pregnancy/started cycle 37/118(31.36 %) 41/118(34.75 %) 0.86[0.5–1.48] 0.578
Ongoing pregnancy/transfer cycle 37/114(32.46 %) 41/118(34.75 %) 0.9[0.52–1.56] 0.708
Implantation rate 49/265(18.49 %) 53/267(19.85 %) 0.92[0.59–1.41] 0.689
Multiple pregnancy rate 7/42(16.67 %) 6/46(13.04 %) 1.33[0.41–4.34] 0.632
Spontaneous abortion rate 5/42(11.9 %) 5/46(10.87 %) 1.11[0.3–4.14] 0.879
Values are expressed as n/n (%) unless otherwise indicated
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levels without adverse effects on embryo quality, the
fertilization rate or the pregnancy rates. The incidence
of moderate/severe OHSS was 4.6 % [8].
The exact mechanism by which GnRH antagonists in-
duce a rapid decline in the estradiol level and reduce the
risk of OHSS is not clear. Several studies have suggested
that GnRH antagonists have a direct effect on the ovary
mediated by interaction with the GnRH-I and GnRH-II
receptors present on granulosa cells [19, 20]. Asimako-
poulos et al. [21] reported that GnRH antagonists inhibit
the production of VEGF from cultured human granulosa
luteinized cells.
In a prospective randomized study, Aboulghar et al.
[9] compared coasting with antagonist rescue protocol
in a series of 192 patients pretreated with GnRH agonist
long protocol who were at high risk for OHSS. None of
the patients in either groups experienced severe OHSS.
The duration of coasting was significantly longer than
the duration of antagonist administration (2.81 ± 0.97 Vs.
1.74 ± 0.91 days; P < 0.001). Antagonist rescue protocol
produced more high quality embryos and more oocytes.
The rapid drop in the estradiol level with antagonist
rescue protocol prevented prolonged deprivation of the
growing follicles from gonadotropins which has a nega-
tive impact on the embryo quality and IVF-ET out-
comes. Moreover, the administration of a low dose of
gonadotropins (75 IU/day) in the antagonist rescue
protocol group supported the function of granulosa cells
and maintained the production of high quality embryos.
Martinaz et al. [22] replaced GnRH agonist with GnRH
antagonist in the early stages of ovarian stimulation
(after 6 to 8 days of gonadotropins administration) in a
series of 19 patients who were at high risk for OHSS
(more than 10 follicles per ovary and/or serum estra-
diol > 900 pg/ml and the follicles expected to need 3 or
more days to reach triggering criteria). The dose of
gonadotropins was reduced and ovulation was triggered
by rHCG in 14 patients and by a GnRH agonist bolus in
5 patients. The mean (SD) duration of antagonistadministration was 4.8 ± 0.8 days. No oocytes were re-
trieved in one patient triggered with a GnRH agonist
bolus. One patient had moderate OHSS. The authors
suggested that early administration of GnRH antagon-
ist could allow triggering of ovulation with GnRH
agonist bolus which is associated with a lower risk of
OHSS compared to triggering ovulation with HCG.
Further studies are needed to determine for how long
pituitary desensitization and unresponsiveness to
GnRH bolus trigger persist after switching GnRH
agonist to GnRH antagonist.
In a retrospective study, Hill et al. [23] replaced GnRH
agonist with GnRH antagonist without reducing the
dose of gonadotropins in 387 patients pretreated with
microdose flare or long luteal agonist protocol who were
at high risk of OHSS. In the majority of patients
(98.45 %), one or two doses of GnRH antagonist were
required to induced a rapid drop in the estradiol level.
Antagonist rescue prevented cycle cancellation, as well
as permitted continued gonadotropin administration and
follicular development and maturation for an additional
one to three days. The incidence of severe OHSS was
8 % and the cycle cancellation rate was 1.5 %.
The higher incidence of severe OHSS in the study
by Hill et al. [23] (8 %) in comparison with our study
(0 %) and the studies of Aboulghar et al. [9] (0 %),
Martinez et al. [22] (0 %) and Gustafson et al. [8]
(2.35 %) may be attributed to differences in the sam-
ple population or the treatment protocol. In the study
by Hill et al. [23], antagonist administration was not
accompanied with adjustment in the dose of gonado-
tropins, whereas the dose of gonadotropins was
reduced in other studies [8, 9, 22]. Moreover, the
duration of antagonist administration was longer in
Martinaz et al. [22] study in comparison with the
study by Hill et al. [23]. Further studies are needed to
investigate the proper timing and duration of antag-
onist administration and the effect of reducing gonad-
otropins dose on the incidence of OHSS, the number
of retrieved oocytes and the embryo quality.
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lower in mild stimulation IVF cycles in comparison to
conventional long agonist IVF cycles [24, 25]. Reducing
gonadotropins dose seems to be effective in minimizing
the risk of OHSS. Large follicles have higher sensitivity to
gonadotropins compared to medium and small sized
follicles, and therefore with reducing the dose of gonado-
tropins, large follicles continue to grow and small and
medium sized follicles become atretic. The atresia of
medium and small sized follicles minimizes the produc-
tion of chemical mediators responsible for development of
OHSS [26]. Moreover, reducing gonadotropins dose slows
the rate of granulosa cells proliferation which produces
the chemical mediators responsible for OHSS [27].
Antagonist rescue protocol and cabergoline minimize the
risk of OHSS by two different mechanisms. Antagonist
rescue protocol inhibits estradiol and VEGF production by
the growing follicles and cabergoline blocks VEGF mediated
increased capillary permeability [2, 21]. This means that
cabergoline augments the effect antagonist rescue protocol.
In the current study, 5000 IU of HCG was used to
trigger final oocyte maturation. The majority of studies
revealed that the reproductive outcomes of IVF-ET cy-
cles are comparable in women receiving 5000 IU or
10000 IU of HCG to trigger final oocyte maturation
[28]. Several authors suggested that the administration
of 5000 IU of HCG instead of 10000 IU of HCG may
minimize the risk of OHSS in patients who have a high
risk for OHSS [28, 29]. On the other hand, two small
studies revealed that the administration of lower doses
of HCG (≤5000 IU) does not reduce the incidence of
OHSS in patients at high risk for OHSS [30, 31].
In the current study, the administration of 5000 IU of
HCG instead of 10000 IU of HCG to trigger final oocyte
maturation may have an additive effect in minimizing the
risk of OHSS in both groups. However, because the same
dose of HCG (5000 IU) was used to trigger final oocyte
maturation in both groups, we do not think that the
administration of 5000 IU of HCG instead of 10000 IU of
HCG is responsible for the greater efficacy of antagonist
rescue protocol combined with cabergoline in minimizing
the risk of OHSS in comparison to cabergoline alone.
The main strength of this study is the prospective ran-
domized controlled design. Our study has two limitations.
First, the patients and the doctors were not blind to the
treatment allocation. Second, it is not clear whether
antagonist administration, HP-uFSH dose reduction to
75 IU/day or the combination of both is responsible for
minimizing the risk of OHSS. Further studies are needed to
clarify this point.
Conclusion
GnRH antagonist rescue protocol (replacing GnRH
agonist with GnRH antagonist and reducing the dose ofgonadotropins to 75 IU/day) combined with cabergoline
is more effective than cabergoline alone in the preven-
tion of OHSS in patients downregulated with GnRH
agonist who are at high risk for OHSS.
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